Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2a, Randomized, Double-Blind, Active Controlled Study to Assess the Preliminary Clinical Efficacy, Safety, Tolerability, and Pharmacokinetics, of CYB004 in Participants With Generalized Anxiety Disorder (GAD) With Depressive Symptoms

Next Previous
Trial Profile

A Phase 1b/2a, Randomized, Double-Blind, Active Controlled Study to Assess the Preliminary Clinical Efficacy, Safety, Tolerability, and Pharmacokinetics, of CYB004 in Participants With Generalized Anxiety Disorder (GAD) With Depressive Symptoms

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CYB 004 (Primary)
  • Indications Generalised anxiety disorder
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Cybin

Most Recent Events

  • 20 May 2025 According to Cybin media release, dosing is ongoing in this phase 2 study in generalized anxiety disorder (GAD) and is expected to complete in mid-2025.
  • 08 Aug 2024 According to Cybin media release, the company anticipates topline safety and efficacy readout from Phase 2 GAD study expected around year end 2024 or early Q1 2025.
  • 26 Jun 2024 According to Cybin media release, the company anticipates topline safety and efficacy readout from Phase 2 GAD study expected around year end 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top